Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.53 |
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 3/20 | 0.48 |
| ▸ | JAK3 | P52333 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13268232 | 0.92 | BRD4 (0.62) | BRD4JAK2FLT3JAK1JAK3 | |
| SCHEMBL13268014 | 0.90 | BRD4 (0.55) | BRD4JAK2FLT3JAK1JAK3 | |
| SCHEMBL13268023 | 0.86 | BRD4 (0.61) | BRD4JAK2FLT3JAK1JAK3 | |
| SCHEMBL12854617 | 0.86 | BRD4 (0.54) | BRD4JAK2FLT3JAK1JAK3 | |
| SCHEMBL13268185 | 0.85 | PDGFRA (0.60) | BRD4JAK2FLT3JAK3TNK2 | |
| SCHEMBL13268225 | 0.85 | JAK1 (0.60) | BRD4JAK2FLT3JAK1JAK3 | |
| SCHEMBL3120300 | 0.85 | BRD4 (0.53) | BRD4JAK2FLT3JAK1JAK3 | |
| SCHEMBL13268245 | 0.84 | BRD4 (0.62) | BRD4JAK2FLT3JAK3TNK2 | |
| SCHEMBL13268016 | 0.84 | BRD4 (0.51) | BRD4JAK2FLT3JAK1JAK3 | |
| SCHEMBL13268042 | 0.83 | TNK2 (0.56) | BRD4FLT3TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | BRD4 758/4885JAK2 854/4885FLT3 516/4885 |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | BRD4 789/4885JAK2 994/4885FLT3 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.